Enavogliflozin, also known as DWP-16001 and GCC-5694A, is an antidiabetic (hypoglycemic) agent. It is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. DWP16001 is currently in a phase 2 clinical trial as a novel anti-diabetes drug for the treatment of type 2 diabetes by selective inhibition of sodium-glucose cotransporter 2.
MedKoo Cat#: 573890
Name: Enavogliflozin
CAS#: 1415472-28-4
Chemical Formula: C24H27ClO6
Exact Mass: 446.1496
Molecular Weight: 446.92
Elemental Analysis: C, 64.50; H, 6.09; Cl, 7.93; O, 21.48
The following data is based on the product molecular weight 446.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
